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This Month in the Journal
This month in the Journal, Mona Shahbazian and Huda
Zoghbi review the current state of knowledge on Rett
syndrome. This disorder of arrested neurological devel-
opment is caused by mutations in MECP2, which en-
codes a protein that binds preferentially to methylated
DNA and is thought to silence transcription of down-
stream genes through recruitment of co-repressor com-
plexes. Beyond covering basic clinical and neurological
features of the syndrome, the review also discusses cur-
rent ideas on the function of MeCP2 and how it might
be involved in this syndrome.
Factor H Dysfunction in Atypical HUS, by Sa´nchez-
Corral et al. (p. 1285)
HF1 encodes factor H, a plasma protein that controls
the function of the alternative complement pathway.
Mutations in HF1 have been found in individuals with
atypical hemolytic uremic syndrome (aHUS), a disorder
characterized by acute renal failure, thrombocytopenia,
and microangiopathic hemolytic anemia. Although sev-
eral HF1 mutations have been found in people with
aHUS, many of these individuals have normal comple-
ment profiles and factor H plasma levels, so it has been
speculated that the protein has altered function. Mis-
sense mutations in HF1 cluster in a region involved in
the binding of factor H to C3b deposited on cellular
surfaces. To determine how these mutations lead to
aHUS, Sa´nchez-Corral et al. assessed the function of
three mutant forms of purified factor H. Although the
ability of the three mutants to control activation of com-
plement was normal, they all exhibited a reduction in
their ability to interact with surface-bound C3b. This
finding is in accordance with the hypothesis that patients
with aHUS have a dysfunction in their ability to protect
cellular surfaces from complement activation, which can
result in tissue damage if complement is activated. This
dysfunction is not the full story, however, because there
are unaffected carriers of at least one of these mutations.
Other factors, such as the level of HF1 expression, may
also play a role in the development of disease. The im-
plications of these findings in terms of treatment of
aHUS are discussed.
RHD Incompatibility and Schizophrenia, by Palmer et
al. (p. 1312)
In several studies, Rh incompatibility has been impli-
cated as a risk factor for schizophrenia. However, these
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earlier studies were not designed in such a way that it
was possible to tease apart whether this effect is actually
due to maternal-fetal genotype incompatibility. It could
be that the risk of schizophrenia associated with this
region is really due to effects of the maternal genotype
alone or to linkage and association with a susceptibility
allele at or near the RHD locus. To unravel this asso-
ciation, Palmer et al. adapt a case-parent–trio log-lin-
ear–modeling approach that can distinguish maternal-
fetal genotype incompatibility from other effects. Their
results do, in fact, suggest that the RHD locus increases
the risk of schizophrenia through a maternal-fetal ge-
notype incompatibility mechanism, which they postulate
may act through hypoxia or an increase in unconjugated
bilirubin, which is neurotoxic.
Male Mouse Autosomal Recombination Maps, by
Froenicke et al. (p. 1353)
Although recombination appears not to be randomly
distributed throughout the genome, the mechanisms
governing its distribution are unclear. In order to ex-
amine these mechanisms, Froenicke et al. determined the
recombination map for each autosome of the male
mouse. In combination with FISH, which was used to
identify individual chromosomes, antibodies to MLH1
(a mismatch repair protein essential for crossover in
mice) were used to determine the positions of crossovers
on these chromosomes. Going further, the authors hy-
bridized genetically mapped BACs to the chromosomes.
This procedure allows Froenicke et al. to begin to in-
tegrate genetic, physical, and cytological maps, in order
to study the relationships between them. Among other
things, their results suggest that synaptonemal-complex
length is correlated with crossover frequency. Additional
factors, such as interference and the temporal order of
synapsis, may also influence recombination distribution.
Haplotype Blocks in Association Studies, by Zhang et
al. (p. 1386)
It has recently been proposed that the human genome
can be partitioned into blocks of limited haplotype di-
versity and that a limited number of SNPs can capture
most of the genetic diversity in these haplotype blocks.
But how does use of these so-called “tag” SNPs affect
the power of association studies? Zhang et al. address
this question through simulations of case-control and
family-trio samples, and they compare three kinds of
data: all of the SNPs in a region and their corresponding
haplotypes, the tag SNPs and their haplotypes, or a set
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of randomly chosen SNPs (equal in number to that of
the tag SNPs) and their haplotypes. The results indicate
that tag SNPs are more powerful than randomly chosen
SNPs and that use of tag SNPs significantly reduces ge-
notyping efforts without significant reductions in study
power. Although these numbers are affected by certain
parameters used in the simulations, Zhang et al. find
that, on average, the use of tag SNPs enables the re-
duction of the genotyping effort by 75% while reducing
the power of a study by only 4%.
A Founder Mutation in MSH2, by Foulkes et al. (p.
1395)
The identification of population-specific founder muta-
tions can facilitate genetic testing, because it allows one
to look first for the most likely mutations before entire
gene sequences need to be screened. Foulkes et al. have
identified an MSH2 founder mutation in the Ashkenazi
Jewish population that may prove to be an important
cause of hereditary nonpolyposis colon cancer (HNPCC)
in this group. In large hospital-based and population-
based samples, they found several unrelated families
who carry this missense mutation, MSH2*1906GrC.
Although MSH2*1906GrC is probably a rare cause of
colorectal cancer, it appears that, among Ashkenazi Jews
with HNPCC that fulfills the Amsterdam criteria, a sig-
nificant fraction of cases are due to this mutation. Thus,
as the identification of founder mutations in BRCA1/2
has made it easier to perform genetic testing in breast
and ovarian cancer patients from this population, the
1906GrC mutation may be useful for genetic testing for
HNPCC in Ashkenazi Jews.
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